HAL Allergy Business Model
Our activities focus on an increasing quality of life for patients in the field of allergy
Rising numbers of people suffering from allergies worldwide demand adequate allergy diagnostic and treatment. Therefore, we focus our research and development activities on improving the quality of life of by providing biopharmaceutical products for causal allergy treatment.
HAL Allergy attracts the professional know-how about allergen immunotherapies and in-vivo diagnostics, for more than 50 years now. With innovative products we contribute to solving the challenges of patients with allergies.
Since its foundation in 1959 the focus is on the allergy business with its research and development, the biopharmaceutical production and sales across European markets. We take pride in our international leading role in the production of allergen extracts, both for therapeutic and diagnostic purposes.
In the course of 2012 HAL Allergy Group established HALIX , a Contract Development Manufacturing Organization (CDMO), based on the experience and know-how of HAL Allergy.
Clear mission and vision stated for the future
HAL Allergy is prepared for worldwide future developments and evolving healthcare needs in the field of allergy treatment. Driven by commitment, partnership and innovation to supply our professional customers with the best convenient-to-use-products to cure patients, HAL Allergy’s mission builds the basis for the future.
Looking into the future, we have the vision to be a full-fledged international biopharmaceutical company, enabling us to provide our professional partners with breakthrough innovations designed to revolutionize curing patients.
HAL Allergy does MORE
HAL Allergy uses the established and proven transformation program ‘MORE’ developed by the Droege Group, by structuring its operational business within an activity based framework. Our aim is to achieve the overarching goal of providing the best possible medical products and scientific output in order to increase quality of life for patients in the field of allergy.
Being a mid-sized business, we follow an entrepreneurial approach. Our strategy is to have a stable and highly skilled organization. This is the basis for a profitable and sustainable growth of our company. The MORE framework helps us to achieve the overriding goal of HAL Allergy. Herewith we are responding proactively to the requirements of our scientific environment and, of course, practitioners and patients’ needs.
How we use the MORE framework in order to achieve our strategic goals
M stands for Maintain
Maintain stands for securing the entire product portfolio. We deliver a significant amount of therapies to the international markets. Basis for this is full compliance with the ‘Therapieallergene- Verordnung (TAV)”, which was put in force by the German Paul-Ehrlich-Institut (PEI) on 14.11.2008. After having successfully finished the TAV, we will be able to strengthen our international market position. In order to achieve this, HAL Allergy invests significantly into the specific expertise of our employees.
O stands for Optimize
We continuously and consequently optimize our value driving processes throughout the group of companies. Our current focus foots on a digitalization strategy for internal and external stakeholders. We strive for a strong leverage, which is derived from the Profit Improvement Program (PIP), the Process Optimization Program (POP) as well as the Sales Force Excellence Program (SFE).
R stands for Reinvent
By reinventing ourselves, we proactively address the challenges of tomorrow. We have a clear commitment to develop new products for patients suffering from allergy. HAL Allergy is engaged in different phases of research ranging from early stage development to pre-clinical and up until registration. The optimization of the existing product portfolio is key: increased user-friendliness of our products for practitioners and patients. Furthermore, we do facilitate growth and know-how development via our contract development manufacturing business unit, where we on the one hand serve our clients but also support meaningful projects in the field of allergy.
E stands for Enhance.
This mainly means expanding our market position by acquisitions or cooperation. However, the major driver for enhancing our business is the successful completion of our clinical trial program. This will increase HAL Allergy’s reach on international markets and introduction of new products. Add-on acquisitions will help in order to increase the HAL Allergy platform.